The magnitude of semaglutide's effects on alcohol consumption appears stronger than existing medications for alcohol use disorder, even at the lowest clinical doses, suggesting tremendous potential for treating addiction. The drug's ability to reduce both alcohol consumption and cravings could revolutionize treatment options for millions struggling with alcohol dependence. The results demonstrate a clear pathway for new therapeutic approaches.
The study's small sample size, short duration, and limited participant demographics cap the broader applicability of these findings. The research excluded individuals who typically seek treatment for severe alcohol use disorder, and potential side effects still need further investigation. Existing approved medications for alcohol use disorder should remain the primary treatment option until more comprehensive research is completed.